Cited by 1,180Tryptophan and brain disordersStress Responses and CortisolTreatment of Major Depression

The DOI matches its Crossref record; 437 of the 445 references it cites were found in a registry or an index; 1 of the 187 sources its claims cite were checked for support.

Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications

Open access
Felger, J.C., Lotrich, F.E.·2013·Neuroscience

Abstract

Mounting evidence indicates that inflammatory cytokines contribute to the development of depression in both medically ill and medically healthy individuals. Cytokines are important for development and normal brain function, and have the ability to influence neurocircuitry and neurotransmitter systems to produce behavioral alterations. Acutely, inflammatory cytokine administration or activation of the innate immune system produces adaptive behavioral responses that promote conservation of energy to combat infection or recovery from injury. However, chronic exposure to elevated inflammatory cytokines and persistent alterations in neurotransmitter systems can lead to neuropsychiatric disorders and depression. Mechanisms of cytokine behavioral effects involve activation of inflammatory signaling pathways in the brain that results in changes in monoamine, glutamate, and neuropeptide systems, and decreases in growth factors, such as brain-derived neurotrophic factor. Furthermore, inflammatory cytokines may serve as mediators of both environmental (e.g. childhood trauma, obesity, stress, and poor sleep) and genetic (functional gene polymorphisms) factors that contribute to depression's development. This review explores the idea that specific gene polymorphisms and neurotransmitter systems can confer protection from or vulnerability to specific symptom dimensions of cytokine-related depression. Additionally, potential therapeutic strategies that target inflammatory cytokine signaling or the consequences of cytokines on neurotransmitter systems in the brain to prevent or reverse cytokine effects on behavior are discussed.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review argues that inflammatory cytokines contribute to a subtype of depression by altering neurotransmitter, neuropeptide, growth-factor, and glutamate systems, with evidence drawn from human and animal studies. It proposes that cytokine-related depression may be identified through inflammatory biomarkers and genetic variants and treated by targeting inflammation or its downstream neural effects.

Key findings

  • Elevated proinflammatory cytokines and markers—including IL-1, IL-6, TNF-alpha, CRP, and PGE2—are reported in idiopathic major depression and in medically ill populations; cancer patients show elevated cytokines and depression/fatigue rates approaching 50%, and IFN-alpha treatment induces depression in 30–50% of patients depending on dose.
  • Peripheral cytokines can reach the brain through circumventricular organs, active transport, vagal afferents, endothelial/perivascular activation, and immune-cell recruitment, then amplify local inflammatory signaling involving COX-2/PGE2, microglia, IDO/KYN metabolites, iNOS, and reactive oxygen/nitrogen species.
  • Specific polymorphisms are linked to particular symptom dimensions: IL-6 rs1800795 with depression but not worsening fatigue during IFN-alpha therapy; TNF-alpha A-308G rs1800629 with irritable anger rather than depression; 5-HTTLPR with neurovegetative symptoms; BDNF Met with more psychological/cognitive symptoms; and IDO1 rs9657182 with IFN-alpha-induced depression in Caucasian C-risk-allele carriers but not African Americans.
  • Therapeutic implications include SSRIs being more effective for mood, anxiety, and cognitive symptoms than for fatigue/neurovegetative symptoms; the TNF antagonist infliximab improved depressive symptoms in treatment-resistant patients only when baseline CRP was high (hsCRP >5 mg/L); other candidates include COX inhibitors, omega-3 fatty acids, p38 MAPK/NF-kB inhibitors, BH4/monoamine-synthesis support, IDO/KYN inhibitors, and NMDA antagonists.

Methods

  • Narrative review synthesizing human clinical studies—including idiopathic major depression, medically ill populations, IFN-alpha-treated patients, CSF and blood biomarker studies, neuroimaging, and genetic association studies—alongside animal and preclinical mechanistic work.
  • The paper integrates evidence across proposed pathways: cytokine access to the brain, monoamine and glutamate neurotransmission, BDNF, CRH/HPA-axis function, and inflammatory signaling.
  • Main analysis is qualitative synthesis; no systematic search strategy, meta-analysis, or formal risk-of-bias assessment is described.

Limitations

  • The paper states that much of the vulnerability and treatment literature relies on correlative relationships among SNPs, inflammatory or neurotransmitter biomarkers, and behavioral symptoms, so mechanistic animal/translational studies and subsequent clinical trials are needed.
  • The paper also states that more human neuroimaging is needed, that peripheral transcriptomic findings should be integrated with brain imaging, and that many studies did not examine biomarkers or polymorphisms in relation to specific depressive symptom dimensions.
  • Evident from the text: as a narrative review, it lacks a systematic search and inclusion process, and many cited findings come from specific populations or preclinical models, which may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.neuroscience.2013.04.060

Cites

437 of 437 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

104 Not checked yet · 24 Own interpretation · 2 Own method · 2 No basis given · 1 Partly supported · accuracy not yet measured

Verify all 186 references — free account

Show all 78 claims

  • It may state two separate claims as one. 53
  • Probably not a substantial claim. 3
55 of 55
  • The paper relies on this without support.

    SSRIs and other classical antidepressants targeting the 5-HT system are efficacious for many aspects of major depression and cytokine-induced depression.

    “Although SRRIs and other classical antidepressants that target the 5-HT system are efficacious in treating many aspects of both major depression and cytokine-induced depression”
  • The paper relies on this without support.

    Knockout mice lacking the ATP P2X7 receptor, which stimulates inflammasome-mediated IL-1beta release, show an antidepressant-like profile with increased mobility in tail suspension and forced swim tests.

    “knockout mice for the ATP P2X7 receptor that stimulates inflammasome-mediated IL-1beta release exhibit an antidepressant-like profile, including increased mobility in the tail suspension and forced swim tests”
  • The paper relies on this without support.

    Classic stimulants increase dopamine release and block DAT function.

    “Classic stimulants act to increase DA release and block DAT function”
3 of 3

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 445 references

Research works printed but not linked: 4

  1. Capuron, 2011, Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms, Biol Psychiatry, 70, 175, 10.1016/j.biopsych.2010.12.006 · DOI · Paper page
  2. Koo, 2010, Nuclear factor-kb is a critical mediator of stress-impaired neurogenesis and depressive behavior, Proc Natl Acad Sci U.., 107, 2669, 10.1073/pnas.0910658107 · DOI · Paper page
  3. O’Connor, 2009, Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice, Mol Psychiatry, 14, 511, 10.1038/sj.mp.4002148 · DOI · Paper page
  4. Zhu, 2010, Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters, Neuropsychopharmacology, 35, 2510, 10.1038/npp.2010.116 · DOI · Paper page

Cited by

Sorted by citations

Items 801–900 of 999

Metadata

Authors
Felger, J. C., & Lotrich, F. E.
Affiliations
  • Emory University (US)
  • University of Pittsburgh (US)
Venue
Neuroscience
Publisher
Elsevier BV
Published
2013-08
Volume
246
Pages
199-229
ISSN
0306-4522 (ISSN-L)
OpenAlex
W2004243143
Cited by
1,180
References
445
Citations by year
2026: 97 · 2025: 125 · 2024: 99 · 2023: 98 · 2022: 127 · 2021: 107 · 2020: 86 · 2019: 104 · 2018: 101 · 2017: 70 · 2016: 60 · 2015: 61 · 2014: 31 · 2013: 12
FWCI
3.84
Type
journal article
Language
en
Open access
Locations
  • Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIMH (R090250)
  • the Glenn Family Breast Fund
  • the Winship Cancer Institute
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
inflammatory cytokines, depression, neuroinflammation, innate immune system, monoaminergic systems, glutamatergic system, neuropeptides, brain-derived neurotrophic factor, genetic polymorphism, childhood trauma, obesity, stress, sleep, neurotransmitter systems, cytokine signaling, anti-inflammatory therapy
MeSH terms
Animals, Antidepressive Agents, Brain, Depression, Humans, Inflammation, Biomarkers, Cytokines, Inflammation Mediators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review